Lipomics Technologies Sign Research Collaboration Agreement for Pharmacometabolic Markers
News May 22, 2007
Lipomics will provide Duke analytical services for biomarker discovery and validation (using its proprietary platform and technologies relating to lipid profiles) as well as provide data transfer and interpretation services that will streamline the process of biomarker development allowing researchers at Duke easy access to analysis and data.
In return, Lipomics will receive an option to license diagnostic rights on all such markers developed under this agreement through use of Lipomics proprietary technologies. Initial clinical areas are CNS (schizophrenia and depression) and Cardiovascular (response to statins) disorders.
Results from the first project of the collaboration were presented at the Society of Biological Psychiatry meeting in San Diego on May 18th, 2007. The study aimed to define metabolic signatures for patients treated with anti-psychotic drugs.
“We are very excited about this partnership. It is a great honor to work with Duke University, one of the leading academic institutions in the country, to advance our clinical diagnostic program” said Dr. Meeta Patnaik, chief medical officer, Lipomics.
Financial terms of the collaboration were not disclosed.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE